Avadel Pharmaceuticals (AVDL) and nference announced the publication of real-world data that identified the demographic characteristics and the top 20 most prevalent comorbidities of people living with narcolepsy. The paper, titled “Demographic Characteristics and Comorbidities of Patients With Narcolepsy: A Propensity-Matched Cohort Study,” was published online in Sleep Advances. These real-world findings were previously presented at the American Neurological Association, ANA, Annual Meeting in October 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Gains FDA Approval for LUMRYZ
- Avadel Pharmaceuticals announces FDA approval of sNDA for LUMRYZ
- Avadel Pharmaceuticals call volume above normal and directionally bullish
- Avadel Pharmaceuticals announces publication of data on LUMRYZ
- Avadel Pharmaceuticals Advances Pediatric Narcolepsy Treatment Review